Modified immune cells battle childhood leukemia in new trial
NCT ID NCT06847269
Summary
This study is testing a treatment called CAR T-cell therapy for children and young adults (up to age 21) whose CD19-positive leukemia has come back or hasn't responded to other treatments. Doctors collect a patient's own immune cells, modify them in a lab to better target cancer, and then infuse them back. The study also aims to find the best dose of a chemotherapy drug (fludarabine) given before the cell infusion and to monitor how long the modified cells last and how well they work.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
St. Jude Children's Research Hospital
RECRUITINGMemphis, Tennessee, 38105, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.